Sun, Dec 21, 2014, 4:44 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Financial News From Zacks Small Cap Research

  • EPRS: Epirus Biopharma: An Intriguing Global Biosimilar Play Zacks Small Cap Research - Fri, Dec 19, 2014 9:00 AM EST

    Epirus Biopharmaceuticals (EPRS) is a biopharma company focused on developing, manufacturing, and commercializing biosimilar therapeutics in various jurisdictions worldwide. The company's strategy is centered on launching biosimilar products in the developed markets (U.S., Europe), accessing growth in local production …

  • Enumeral Biomedical Holdings, Inc. (ENUM) is a biotechnology company focused on discovering and developing novel immunotherapies for the treatment of cancer and autoimmune diseases. On December 18, 2014, Enumeral announced it entered into a partnership with Merck to identify functional responses of Merck’s immuno-therapeutics …

  • CTSOD: Fresenius Adds More Than Just Marketing Muscle Zacks Small Cap Research - Thu, Dec 18, 2014 10:00 AM EST

    Fresenius’ distribution reach including in France, which is the second largest market for medical devices in Europe, will almost certainly be a material needle-mover of CTSO’s revenue.  But Fresenius brings much more than just a large dialysis service/equipment/supplies network.  Fresenius is THE leader in dialysis, has …

  • ASPX: Auspex Pharma Hits A Homerun In Phase 3 Huntington's Chorea Trial Zacks Small Cap Research - Wed, Dec 17, 2014 12:00 PM EST

    The two Phase 3 trials, First-HD and Arc-HD, studied SD-809, a deuterium-containing analog of tetrabenazine, head-to-head vs. placebo for the treatment of chorea with HD and in transitioning patients on stable doses of tetrabenazine to SD-809, respectively. We initiated coverage of Auspex Pharma in November 2014 with a …

  • APDN Reports Record Revenue for Fiscal Year 2014 Zacks Small Cap Research - Wed, Dec 17, 2014 9:15 AM EST

    By Grant Zeng, CFA NASDAQ:APDN On December 16, 2014, Applied DNA Sciences (NASDAQ:APDN) reported its year-end results of fiscal 2014 ended September 30, 2014. For the fiscal year ended September 30, 2014, ...

  • NVIV: FDA Allows InVivo Therapeutics To Expedite Enrollment For Spinal Injury Device Zacks Small Cap Research - Tue, Dec 16, 2014 3:00 PM EST

    On December 16, 2014, InVivo Therapeutics (NVIV) released some very positive news with respect to the company's going pilot study (NCT02138110) testing InVivo's Neural-Spina Scaffolding ("NSS") for the treatment of complete traumatic spinal cord injury. It's primarily a safety study, with investigators and the FDA looks …

  • VPIG: Believe Larger Partner Could Help Grow Oink Zacks Small Cap Research - Tue, Dec 16, 2014 1:00 PM EST

    Last week, Virtual Piggy (VPIG) announced that its board had authorized management to evaluate strategic alternatives. We believe Virtual Piggy could be an interesting acquisition candidate for a larger technology company or payment provider seeking to expand within the YA market in a regulatory compliant way. Many online …

  • SRNE: Sorrento Establishes Collaboration with Nantworks Zacks Small Cap Research - Tue, Dec 16, 2014 9:25 AM EST

    On Dec. 15, 2014, Sorrento (SRNE) announced that it has entered into a binding agreement with NantWorks founder, physician scientist, and biotechnology entrepreneur Dr. Patrick Soon-Shiong. Pursuant to the agreement, NantWorks and Sorrento will establish a first joint venture to jointly develop next generation immunotherapies …

  • Advaxis (ADXS), a clinical stage biopharmaceutical company, announced on December 15, 2014 that the FDA has cleared its Investigational New Drug (IND) application for combinational use of ADXS-HPV and MedImmune’s anti-PD-L1 immune checkpoint inhibitor, MEID4736. The Phase I/II trial will begin enrollment in early 2015 …

  • PURE Reports Fiscal First Quarter 2015 Financial Results Zacks Small Cap Research - Fri, Dec 12, 2014 12:45 PM EST

    By Grant Zeng, CFA OTC:PURE On Dec 11, 2014, PURE (OTC:PURE) reported financial results for the fiscal 1Q15 ended October 31, 2014. Revenues for the fiscal 1Q15 were $117,000, compared to $115,000 for ...

  • By Anthony Schwartz, PhD NASDAQ:CPXX Celator Pharmaceuticals (NASDAQ:CPXX)  is a clinical stage biopharmaceutical company developing novel formulations of currently approved drugs to treat various cancers. ...

  • SANW: Mark Harvey appointed Chairman and Mark Wong will join the board as a Director. Zacks Small Cap Research - Fri, Dec 12, 2014 9:00 AM EST

    On December 11, 2014 S&W Seed (SANW) announced changes to the Board of Directors with Mark Harvey becoming Chairman and Mark Wong joining the board. Mark Harvey was one of the founding members of Seed Genetics International of S. Australia before it was acquired by S&W Seed in April 2013 and he became a member of the Board …

  • OMBP: Omni Bio's Hand Gets Stronger As AAT Shows Potential In GvHD Zacks Small Cap Research - Thu, Dec 11, 2014 10:00 AM EST

    Last month we posted an article talking about Omni BioPharmaceuticals, Inc. (OMBP) and data from a Phase 1 study presented at the American Heart Association (AHA) meeting showing encouraging biomarker activity seen with the treatment of plasma-derived alpha-1 antitrypsin (pAAT) in ten patients post acute ST-elevation myocardial …

  • PBIO: Pressure BioSciences Ships Third Barozyme HT48 System for Evaluation Zacks Small Cap Research - Thu, Dec 11, 2014 9:00 AM EST

    On December 10, 2014, Pressure BioSciences (PBIO) announced it has shipped third Barozyme HT48 system to the laboratory of Dr. William E. Funk of the Feinberg School of Medicine at Northwestern University for evaluation. The Funk Laboratory is a current customer of the Company's patented pressure cycling technology (PCT) …

  • SANW: Another stevia plant patent filed. Zacks Small Cap Research - Tue, Dec 9, 2014 5:15 PM EST

    By Ian Gilson, PhD, CFA NASDAQ:SANW S&W Seed (NASDAQ:SANW) announced on Dec. 09, 2014 that it has filed for a patent on a stevia variety, SW201. This is the second filing for a stevia variety by the company. ...

  • SANW: Grover Wickersham retires as Chairman but remains as a director Zacks Small Cap Research - Tue, Dec 9, 2014 9:15 AM EST

    On December 08, S&W Seed (SANW) announced that Grover Wickersham would step down from the post of Chairman of the Board prior to year end 2014 but would remain a Director of the company. Mr. Wickersham founded S&W Seed as it is today after he acquired the partnership that had owned it.

  • LEDIF: $9M - $11M Revenue Guidance Reiterated Zacks Small Cap Research - Mon, Dec 8, 2014 1:00 PM EST

    Along with regaining growth of the company's proprietary VELscope oral cancer screening device, one of the first orders of business of the new leadership was to diversify their revenue base via high-potential new product offerings.  Gane and his team, relying on their expertise, experience and first-had knowledge of market …

  • By Anthony Schwartz, PhD NASDAQ:ADXS Advaxis (NASDAQ:ADXS), a clinical stage biopharmaceutical company, announced on December 8, 2014 that the FDA has cleared its Investigational New Drug (IND) application ...

  • V.ZMS: Q4 Results, Maintaining Outperform Rating Zacks Small Cap Research - Mon, Dec 8, 2014 9:00 AM EST

    In addition, new potential opportunities continue to materialize which could spark even greater demand for the LFS crystals over the long-term.  This includes an initial shipment in November of a $500k order of crystals to the NIITFA Automation Research Centre for Technical Physics (in Russia) related to the development …

  • BioLight : Q3 Interim Results – Getting Ready To Launch Products in 2015 Zacks Small Cap Research - Thu, Dec 4, 2014 8:00 AM EST

    BioLight (BLGTY) has been successful in achieving their targeted milestones. In the last two quarters the company has been busy presenting their technology at Ophthalmology conferences as well as progressing with clinical trials of their cancer diagnostic products. We recently had the opportunity to speak with BioLight's …

  • The TLC-2000 Biofeedback Laser System is a fully automated wireless technology driven by a tablet. We believe that this device with its unique tissue sensing technology has the scientific backing to displace competitive devices. Theralase has also obtained a unique CPT code for reimbursement purposes in the U.S. market. …

  • CPXX: The DSMB Recommends Phase III to Continue Zacks Small Cap Research - Wed, Dec 3, 2014 8:00 AM EST

    On Dec. 1, 2014, Celator (CPXX) announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase III clinical study of CPX-351 has completed a second planned safety review and recommended that the study continue as planned without any modifications. The DSMB decision was based on the safety …

  • PRTX: We're Buyers of Protalex Following Impressive Data At ACR Zacks Small Cap Research - Tue, Dec 2, 2014 10:00 AM EST

    On November 17, 2014, Protalex, Inc. (PRTX) announced that data from Cohorts 1 through 5 of study PRTX-100-104 was presented at a poster session at the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) Annual Meeting 2014.

  • SANW: First Stevia patent applied for with more to come Zacks Small Cap Research - Tue, Dec 2, 2014 9:20 AM EST

    It was in the progress of  compiling data and preparing for patent applications (please note the plural) for stevia varieties (plural again) with improved flavor profiles. Today the company announced that it has filed for one stevia plant variety known as SW107.

  • NWBO: New Financings Boost Balance Sheet Zacks Small Cap Research - Mon, Dec 1, 2014 12:10 PM EST

    By Grant Zeng, CFA NASDAQ:NWBO On Nov 19, NWBO (NASDAQ:NWBO) reported financials for the third quarter of 2014 ended September 30, 2014. Total revenue was $0.58 million, which was from Grant and other ...

  • POZN: Pozen Seeking New Partner For Yosprala Zacks Small Cap Research - Mon, Dec 1, 2014 11:00 AM EST

    This morning Pozen, Inc. (POZN) announced that the company and Sanofi U.S. have mutually agreed to terminate their agreement for the commercialization of Yosprala in the U.S. Yosprala, formerly known as PA, is Pozen's "safer aspirin" product containing either 325 mg or 81 mg of enteric-coated aspirin surrounded by 40 mg …

  • QCRH: Breakout Year Expected in 2015 Zacks Small Cap Research - Tue, Nov 25, 2014 9:30 AM EST

    By Ann Heffron, CFA, CPA  NASDAQ:QCRH We expect 2015 to be a breakout year for QCRH (NASDAQ:QCRH) , and are now estimating a 14% gain in diluted EPS to $2.10, up from $1.93 previously. Click here to download ...

  • This Phase II clinical trial will be a multicenter investigator sponsored trial (IST), with UCSF and Dr. Alain Algazi as the sponsor. Merck will supply pembrolizumab, and OncoSec will provide electroporation devices and plasmid IL-12. Immune checkpoint inhibition is the one of the most promising area for the treatment …

  • CTTC: International Sales Push Revenue To 3-Yr High Zacks Small Cap Research - Mon, Nov 24, 2014 3:30 PM EST

    By Brian Marckx, CFA OTC:CTTC Q3 2014 Results:   Revenue Jumps As Re-Established Int'l Territories Already Making Big Contribution…   Calmare Therapeutics (OTC:CTTC) reported financial results for the ...

  • OMBP: Omni Bio Encouraged By Early-Stage Data At American Heart Association Meeting Zacks Small Cap Research - Fri, Nov 21, 2014 1:00 PM EST

    On November 19, 2014, Omni Bio Pharmaceuticals, Inc. (OMBP) presented data from a Phase 1 clinical trial studying the effects of a single dose of plasma-derived alpha-1 antitrypsin (p-AAT) in ten patients post acute ST-elevation myocardial infarction ("STEMI"). The goal of the study (NCT01936896) was to determine whether …

  • GOVX: GeoVax Reports 2014 Third Quarter Financial Results with Conservative Cash Burn Zacks Small Cap Research - Fri, Nov 21, 2014 10:00 AM EST

    These revenues were related to grants from the NIH in support of its HIV/AIDS vaccine development efforts. R&D expenses include direct costs funded by NIH grants, as well as vaccine manufacturing and testing costs and expenses related to the Company’s HIV immunotherapy program. As of September 30, 2014, GeoVax held a …

  • SANW: Entering the Republic of Turkey with alfalfa seed sales to a distributor. Zacks Small Cap Research - Fri, Nov 21, 2014 9:00 AM EST

    S&W Seed (SANW) announced on Nov. 20, 2014 that it has made its first sale to a distributor in the Republic of Turkey. The company is likely to expand the number of distributors in Turkey as part of its strategy of geographical diversification. The initial sales will be of seed varieties already registered in Turkey by …

  • FPMI: CardioPET Data A Catalyst to Share Price Appreciation Zacks Small Cap Research - Thu, Nov 20, 2014 2:15 PM EST

    By Brian Marckx, CFA OTC:FPMI We have updated our report on FluoroPharma Medical (OTC:FPMI).  See below for free access to our full report on the company.    Development of FluoroPharma's CardioPET nuclear ...

  • ADXS: New Jersey Technology Business Tax Program Grants Advaxis $1.7M Tax Credit Zacks Small Cap Research - Thu, Nov 20, 2014 11:30 AM EST

    By Anthony Schwartz, PhD NASDAQ:ADXS Advaxis (NASDAQ:ADXS), a clinical stage biopharmaceutical company, announced on November 20, 2014 that the New Jersey Technology Business Tax Certificate Transfer (NOL) ...

  • Dejour Energy: 3rd Quarter Results, Woodrush/Hunter Project Update Zacks Small Cap Research - Thu, Nov 20, 2014 8:00 AM EST

    Dejour Energy (DEJ.TO) (DEJ) reported results for the third quarter ending September 30, 2014. Gross oil and gas revenues (before royalties) declined 5.9% Year-Over-Year (YOY) to $2.26 million, which was primarily due to the sale of a 65% working interest in the Kokopelli Project (including the four producing natural gas …

  • AMBS: Astute Deal Brings In Another Shot On Goal For Amarantus Bio Zacks Small Cap Research - Wed, Nov 19, 2014 2:30 PM EST

    On November 17, 2014, Amarantus Bioscience Holdings, Inc. (AMBS) announced that it has entered into an exclusive option agreement with Lonza Walkersville, Inc. to acquire Cutanogen Corporation. Both Lonza Walkersville and Cutanogen Corp. are subsidiaries of Lonza Group Ltd. Acquiring Cutanogen gives Amarantus rights to …

  • Cynapsus Set For Major Revaluation On Positive Phase 2 Data Zacks Small Cap Research - Wed, Nov 19, 2014 10:00 AM EST

    On November 19, 2014, Cynapsus Therapeutics Inc. (CYNAF) (CTH.V) announced what looks to be a clear demonstration of proof-of-concept via positive top-line results from the CTH-105 Phase 2 clinical trial. The CTH-105 study was the first to test Cynapsus APL-130277, a fast-acting, sublingual, thin filmstrip formulation …

  • PBIO Reports 14% Product Revenue Growth for 3Q14 Zacks Small Cap Research - Wed, Nov 19, 2014 9:00 AM EST

    Total revenue for 3Q14 was $372,545, compared to $420,762 for the same period in 2013, an 11% decrease.

  • ILIU: Awareness Building, PerioPredict Adoption Growing Zacks Small Cap Research - Tue, Nov 18, 2014 3:45 PM EST

    ILIU further bolstered these efforts over the last few months and scored additional significant recognition.  This included receiving the 2014 DrBiscupid Dental Excellence Award for PerioPredict as the "Best New Hygienist Product" in October and the authors (including ILIU's own Dr. Ken Kornman and Dr. Lynn Doucette-Stamm) …

  • PRGB: Scoring Successes in Product & Svcs Biz Zacks Small Cap Research - Tue, Nov 18, 2014 11:10 AM EST

    By Brian Marckx, CFA   OBB:PRGB Q3 Update: InSphero Partnership Already Bearing Fruit, 2 High-Profile Customers Buy LAESI Systems… Protea Biosciences (OBB:PRGB) filed their 10-Q for the third quarter ending ...

  • CTSO Remains Highly Undervalued Zacks Small Cap Research - Tue, Nov 18, 2014 9:15 AM EST

    CytoSorbents (CTSO) reported results for the third quarter ending September 30, 2014.  The streak of setting a new record in product revenue was extended to seven straight quarters with Q3 product revenue coming in at $1.0 million, an increase of 276% and 56% from Q3 2013 (i.e. Awareness-building to key opinion leaders …

  • Northstar Healthcare reports 3Q; Zacks raises target to $2.54 Zacks Small Cap Research - Tue, Nov 18, 2014 9:00 AM EST

    On November 13, 2014, Northstar Healthcare (NHC.TO) reported financial results for the third quarter ending September 30, 2014. Net patient revenues continue to grow significantly, driven by the company’s marketing campaigns (especially for bariatric procedures) and the contributions from the expanded operational platform, …

  • On November 10, Soligenix (SNGX) reported financial results for the third quarter ended September 30, 2014.

  • ULUR: Quick Look At ULURU's Third Quarter And Business Fundamentals Zacks Small Cap Research - Mon, Nov 17, 2014 3:00 PM EST

    On November 17, 2014, ULURU, Inc. (ULUR) reported financial results and filed its Form 10-Q for the third quarter 2014, which corresponded to the three month period ending September 30, 2014. For example, earlier in November, ULURU, Inc. signed up an exclusive distribution agreement for 17 Middle East and North African …

  • SNWV: Expect DMC Recommendation in Q1 Zacks Small Cap Research - Mon, Nov 17, 2014 10:30 AM EST

    > On September 9th SANUWAVE announced the Data Monitoring Committee (DMC) overseeing data analysis of the company's supplemental dermaPACE trial recommended, following analysis of the first 90 patients (i.e.

  • By Anthony Schwartz, PhD  NASDAQ:THLD Threshold Pharmaceuticals (NASDAQ:THLD)  is a clinical stage biopharmaceutical company currently evaluating its lead compound, TH-302, in several clinical trials for ...

  • 2015 Will Be The Year Nuo Therapeutics Shines Zacks Small Cap Research - Fri, Nov 14, 2014 1:00 PM EST

    On November 13, 2014, Nuo Therapeutics, Inc. (OTC:NUOT) reported financial results for the third quarter ending September 30, 2014. Revenues were driven by $1.20 million in product sales derived from both Angel and Aurix and $0.49 million in licensing fees, royalties, and other revenue related to the company’s licensing …

  • ENSV: Enservco Reports 3Q; Capacity Expansion Program on Track Zacks Small Cap Research - Fri, Nov 14, 2014 8:00 AM EST

    In addition, management opportunistically acquired a package of oilfield service assets, including 12 hot oil trucks, a frac water heating unit and a 6-acre operating yard near Tioga, North Dakota in order to serve the northern Bakken Shale Region of the Williston Basin. Revenues of the Well Enhancement segment (hot oiling, …

  • CDTI: Restructuring debt schedule improves near term cash flow. Zacks Small Cap Research - Thu, Nov 13, 2014 10:00 PM EST

    By Ian Gilson, PhD, CFA NASDAQ:CDTI On Nov. 13, 2014 CDTi (NASDAQ:CDTI) agreed with its principle lender, and largest stockholder, Kanis S. A. to extend the maturity dates on several notes in return for ...

  • APDN: Price Target Adjusted Reflecting Recent Reverse Stock Split Zacks Small Cap Research - Thu, Nov 13, 2014 2:00 PM EST

    We adjust our price target for Applied DNA Sciences (APDN) to $12 per share reflecting the Company’s recent 1-for-60 reverse stock split. On October 29, 2014, APDN announced a 1-for-60 reverse split of its common stock.

Next >>